曲安奈德玻璃体注射治疗视网膜中央静脉阻塞继发黄斑水肿

目的 观察玻璃体腔曲安奈德注射(intravitreal triamcinolone acetonide,IVTA)治疗视网膜中央静脉阻塞(central retinal vein occlusion,CRVO)继发的黄斑水肿的近期疗效和并发症.方法 对30例(30只眼)CRVO继发的严重黄斑水肿患者,患眼行IVTA 4mg/0.1ml,观察治疗前和治疗后1 d、3 d、1周、1个月、3个月时患者的最佳矫正视力、眼压、眼内炎性反应、晶体、眼底改变,光学相干断层扫描(optic coherenttomography,OCT)测定黄斑区视网膜厚度变化.结果 30只眼中,有22只眼(73%)视力提高,3只眼(10%)视力不变,2只眼(7%)继发性青光眼,2只眼(7%)并发性白内障,1只眼(3%)视网膜脱离.LogMAR视力治疗前为0.78±0.50,治疗后1周、1个月、3个月时分别为0.62±0.48,0.45±0.37,0.31±0.28.黄斑中心凹平均厚度治疗前为(589±132)μm,治疗后1周、1个月、3个月时分别为:(341±122)μm;(201±61)μm;(162±41)μm.治疗前后比较差异有统计学意义(P＜0.01).30只眼中有5只眼(17%)治疗后暂时性眼压轻度升高,经局部药物短期治疗后恢复正常;2只眼(7%)继发性青光眼,给与小梁切除术治疗;2只眼(7%)并发性白内障;1只眼(3%)视网膜脱离,给与激光光凝治疗.结论 IVTA可以在短期内有效地治疗CRVO继发的黄斑水肿,但其并发症不容忽视.     

后Tenon囊下注射曲安奈德联合玻璃体切割术在脉络膜脱离型视网膜脱离中的应用

背景 曲安奈德具有抗光作用,脉络膜脱离型视网膜脱离(RD/CD)术前玻璃体腔内注射TA可减轻炎症反应,改善手术效果,但由于术前眼压低,玻璃体腔注射易引起并发症.关于后Tenon囊下注射TA在RD/CD中的有效性和安全性尚未见报道. 目的 探讨后Tenon囊下注射TA治疗RD/CD的疗效及安全性.方法 采用回顾性研究方法,收集于2010年5月至2014年6月在温州医科大学附属眼视光医院首诊为RD/CD且接受手术的患者22例22眼的病历资料,患眼均于玻璃体切割术前5d行后Tenon囊下注射TA混悬液40 mg(0.4 ml),注药后观察葡萄膜的炎性反应.使用Goldmann眼压计和B型超声仪观察注药前及注药后5d患眼眼压、脉络膜脱离高度及脱离范围的变化,同时监测血压及血糖的变化,并于注药5d后行玻璃体切割术,所有患者术后随访3个月以上. 结果 行TA的后Tenon囊下注射的22眼葡萄膜炎症状均不同程度减轻;注药前患眼平均眼压为(5.4--.2.9) mmHg(1 mmHg=0.133 kPa),注射TA后5d患眼平均眼压为(8.2±4.3) mmHg,眼压上升2.8 mmHg,差异有统计学意义(t=3.430,P＜0.01).注药前患眼平均脉络膜脱离高度为5.2(3.1,6.6)mm,注药后5d平均脉络膜脱离高度为0.9(0,3.8)mm,脉络膜脱离高度显著降低,差异有统计学意义(Z=-4.198,P＜0.01).注药前患眼平均脉络膜脱离范围为12(10,12)个点位,注药后5d平均脉络膜脱离范围为3(0,6)个点位,脱离范围显著下降,差异有统计学意义(Z=-4.124,P＜0.01).患者注药前后血糖、血压变化的差异均无统计学意义(均P＞0.05).术眼术前、术后1个月和3个月LogMAR视力分别为2.14±0.46、1.29±0.57和1.17±0.55,术后视力较术前明显好转,总体比较差异有统计学意义(F=22.060,P＜0.001).视网膜复位率为95.5％.7眼术后出现高眼压,其中5眼使用局部降眼压药物治疗后恢复,2眼药物取出后眼压恢复正常. 结论 RD/CD术前行TA后Tenon囊下注射能减轻术眼葡萄膜炎反应,升高眼压及降低脉络膜脱离,对血糖、血压影响小.     

曲安奈德玻璃体注射治疗视网膜分支静脉阻塞继发黄斑水肿

目的观察玻璃体腔曲安奈德注射(intravitrealtriamcinoloneacetonide,IVTA)治疗视网膜分支静脉阻塞(branchretinalveinocclusion,BRVO)继发的黄斑水肿的近期疗效和安全性。方法对23例(23眼)BRVO继发的严重黄斑水肿患者,患眼行IVTA4mg/0.1ml,观察治疗前和治疗后1天、3天、1周、1个月、3个月时患者的最佳矫正视力、眼压、眼内炎性反应、晶体、眼底改变,光学相干断层扫描(opticcoherenttomography,OCT)测定黄斑区视网膜厚度变化。结果所有23眼中,有20眼(86.9%)视力提高,3眼(13.1%)视力不变。LogMAR视力治疗前为:0.75±0.48,治疗后一周、一个月、三个月时分别为:0.57±0.43;0.38±0.32;0.29±0.29。黄斑中心凹平均厚度治疗前为611±149μm,治疗后一周、一个月、三个月时分别为:325±129μm;208±55μm;173±38μm。治疗前后比较差异有统计学意义(P<0.01)。23眼中有3眼(13.1%)治疗后暂时性眼压轻度升高,经局部药物短期治疗后恢复正常。所有患眼未出现眼内炎、白内障、视网膜脱离、玻璃体出血等并发症。结论IVTA可以在短期内安全有效地治疗BRVO继发的黄斑水肿。     

曲安奈德玻璃体腔注射治疗脉络膜脱离型视网膜脱离的初步研究

目的探讨玻璃体腔注射曲安奈德治疗脉络膜脱离型视网膜脱离的疗效及安全性。方法选择未经有效治疗的脉络膜脱离型视网膜脱离患者,于手术前经睫状体平坦部向玻璃体腔内注入曲安奈德混悬液0．1ml(4mg),注药后观察葡萄膜炎反应及脉络膜脱离消失情况,并于5—10d后行视网膜脱离复位手术。结果有葡萄膜炎反应的13只眼其症状均不同程度减轻,裂孔检出率由注药前的2／13只眼提高至注药后的7／13只眼,绝大多数脉络膜脱离眼于注药后10d内消失,5只眼采用巩膜扣带术,6只眼采用玻璃体切除联合眼内填充术,2例患者放弃手术治疗。手术后平均随访4．45个月,接受手术者最终视网膜全部复位,无1例出现全身应用糖皮质激素的副作用。结论玻璃体腔注射曲安奈德能迅速、安全、有效地治疗脉络膜脱离型视网膜脱离,减轻葡萄膜炎反应,提高脉络膜脱离型视网膜脱离的手术复位率。(中华眼科杂志,2005,41：606-609)     

Retinal toxicity of triamcinolone’s vehicle (benzyl alcohol): an electrophysiologic and electron microscopic study

Purpose To assess retinal toxicity of the vehicle of triamcinolone, benzyl alcohol (BA), when injected into the vitreous cavity of rabbits. Methods This prospective comparative experimental study included 24 pigmented rabbits assigned into two groups: group 1 (experimental, n = 12) received intravitreal 0.1 ml of BA, and group 2 (control, n = 12) received intravitreal 0.1 ml of balanced salt solution (BSS); all injections were done in the right eyes. Clinical examinations [slit lamp biomicroscopy, indirect ophthalmoloscopy, and three intraocular pressure (IOP) measurements] were done on both eyes before injection, at 1 and 3 h post injection, together with electroretinograms (ERGs) at 3 days, 1, 2, 4, and 6 weeks following injections. Three rabbits from each group were euthanased at 1, 2, 4, or 6 weeks and eyes were sent for light and electron microscopic examination for quantitative morphometric measurements. Results The mean amplitudes of the a and b waves of the BA-injected eyes were 6.42 ± 9.02 μv and 11.18 ± 15.18 μv at 3 days, respectively, which were significantly reduced compared with the BSS-injected eyes (30.87 ± 8.22 μv and 57.90 ± 13.38 μv, respectively; P < 0.01 t-test) and the non-injected contralateral eyes (36.20 ± 7.85 μv and 64.10 ± 9.36 μv, respectively; P < 0.01 t-test). These ERG responses continued to be significantly reduced in the BA-injected eyes (P < 0.01 t-test) throughout the study period. The mean ganglion cell count was significantly reduced (P < 0.005 t-test) in the BA-injected eyes (8.42 ± 2.4) compared with the BSS- and non-injected eyes (16.42 ± 3.9 and 16.5 ± 4.2, respectively). The mean thicknesses of the inner nuclear layer (INL) and outer nuclear layer (ONL) were significantly reduced (P < 0.005 t-test) in the BA-injected eyes (3.78 ± 0.96 μm and 11.77 ± 1.29 μm, respectively) compared with the BSS- (6.1 ± 0.92 μm and 21.82 ± 0.95 μm, respectively) and non-injected eyes (7.05 ± 1.9 μm and 22.49 ± 1.01 μm, respectively). Electron microscopy showed moderate to severe intracellular changes in the ganglion cell layer, INL, ONL, and photoreceptor layer at 6 weeks in BA-injected eyes, with no significant changes in BSS-injected eye. There was no significant rise in the IOP or clinical evidence of increased lens density during the study period in any of the eyes. Conclusions Triamcinolone acetonide’s vehicle, BA, produced severe ERG and structural damage to the retina when injected intravitreally.     

Remodeling of the vascular channels in retinal angiomatous proliferations treated with intravitreal triamcinolone acetonide and photodynamic therapy

Background The objective was to describe the remodeling of the vascular channels in stage II retinal angiomatous proliferation (RAP) treated by intravitreal injections of triamcinolone acetonide (TA) and subsequent photodynamic therapy (PDT). Methods Stage II RAP secondary to age-related macular degeneration was documented by dynamic digital fluorescein and indocyanine green angiography in 3 consecutive patients (3 eyes). All eyes were treated with intravitreal injection of TA (4 mg, 0.1 ml) followed by PDT 5–10 days later. Results Indocyanine green angiography (ICGA) revealed a complete remodeling of the vascular structure of the three RAPs after treatment. The feeding retinal artery, which shunted a major part of the blood flow from the original arteriole toward the intraretinal neovascular complex before treatment, regained a normal appearance after treatment. With RAP closure, the blood flow was again directed through the original retinal arteriole, and the connection to the RAP was no longer visible. Conclusions Stage II RAPs are difficult lesions to treat. A real remodeling of the vascular lesion is achieved with the combined use of intravitreal TA and PDT. This finding corroborates the need for randomized clinical trials currently under way to evaluate this combination treatment in wet, age-related macular degeneration.     

曲安奈德溶媒视网膜毒性的形态学研究

目的探讨两种商用曲安奈德(TA)溶媒的视网膜毒性及其与剂量的关系。方法用梯度离心法从两种TA注射液提取高纯度溶媒A、溶媒B。36只新西兰白兔右眼玻璃体内分别注入0.1mL和0.2mL溶媒A、溶媒B及平衡盐溶液。术前、术后定时行眼前节、检眼镜检查及眼底照相;荧光素眼底血管造影(FFA)观察血管病变;光镜、透射电镜观察视网膜结构。结果眼底和FFA检查显示溶媒B引起视网膜血管损害和有髓神经纤维水肿。两种溶媒均引起视网膜结构及光感受器超微结构损害,且随剂量增加而加重;溶媒B引起的损害较溶媒A更显著。结论两种溶媒可引起无色素兔眼不同程度的视网膜损害,并随剂量增加而加重。     

曲安奈德玻璃体腔注射对氧诱导视网膜新生血管的抑制作用及机制

目的 观察曲安奈德(TA)玻璃体腔注射对氧诱导视网膜新生血管的抑制作用,探讨其作用机制.方法 7日龄C57BL/6新生小鼠48只,随机分为正常对照组、单纯高氧组、TA正常组及TA高氧组,分别为6、6、18、18只.单纯高氧组及TA高氧组建立氧诱导视网膜新生血管模型.选取TA正常组及TA高氧组小鼠1只眼,玻璃体腔注射20μg/μl的TA 2 μl;对侧眼注射相同体积的平衡盐溶液(BSS)作为BBS正常组和BBS高氧组.小鼠17日龄时,各组作石蜡切片苏木精-伊红(HE)染色,观察并统计每张切片突破视网膜内界膜的血管内皮细胞核数.TA正常组、BSS正常组、TA高氧组及BSS高氧组作石蜡切片免疫组织化学染色,检测血管内皮生长因子(VEGF)、基质细胞衍生因子1(SDF-1)及CD14的平均吸光度[A,旧称光密度(OD)]值.并行荧光实时定量聚合酶链反应(PCR),检测VEGF及SDF-1的mRNA表达.结果 正常对照组、单纯高氧组、TA正常组、BSS对照组、TA高氧组及BSS高氧组突破视网膜内界膜的血管内皮细胞核数分别为0、675、0、0、110及688个.正常对照组较单纯高氧组明显减少,差异有统计学意义(t=30.62,P＜0.05).TA高氧组较BSS高氧组显著减少,差异有统计学意义(t=19.532,P＜0.05).TA正常组与BSS正常组VEGF、SDF-1及CD14平均A值比较,差异无统计学意义(t=0.161,0.284,0.223;P＞0.05).TA高氧组VEGF、SDF-1及CD14平均A值较BSS高氧组减少,差异有统计学意义(t=-2.264,-2.358,-4.897;P＜0.05).TA正常组与BSS正常组VEGF及SDF-1 mRNA表达比较,差异无统计学意义(t=-0.497,-0.709;P＜0.05).TA高氧组与BSS高氧组VEGF及SDF-1 mRNA表达比较,差异均有统计学意义(Z=-5.137,-4.411;P＜0.05).结论 玻璃体腔注射TA能有效抑制氧诱导视网膜新生血管形成,其抑制作用可能是通过降低VEGF及SDF-1的表达而实现.     

玻璃体腔内注射曲安奈德治疗视网膜静脉阻塞继发黄斑水肿的临床观察

目的观察玻璃体腔内注射曲安奈德(TA)治疗视网膜静脉阻塞(RVO)继发黄斑水肿的临床效果及安全性。方法收集我院2013年1~6月收治RVO继发黄斑水肿患者23例(23只眼),给予玻璃体腔内注射TA0.1 ml(4 mg),术后3个月复查荧光素眼底血管造影及相干光断层成像,观察黄斑水肿的变化。结果视力提高2行或以上12只眼(52.17%),视力波动在1行以内8只眼(30.43%),视力无变化3只眼(13.04%)。黄斑水肿减退、渗漏消失8只眼(34.78%),黄斑水肿减轻、渗漏明显减少13只眼(56.52%),黄斑水肿、渗漏不变2只眼(8.7%)。黄斑中心凹平均厚度为(301.25±87.49)μm。并发症:1只眼术后第1天出现了眼压增高,用降眼压药物控制正常后无复发。1只眼术后第1天出现了假性前房积脓,观察1周后积脓消失。结论玻璃体腔内注射TA治疗RVO继发黄斑水肿是一种有效且安全可行的方法。     

曲安奈德玻璃体腔注射治疗视网膜静脉阻塞和糖尿病视网膜病变继发黄斑水肿分析

目的 观察玻璃体腔注射曲安奈德(TA)治疗视网膜静脉阻塞(RVO)继发黄斑水肿和糖尿病性黄斑水肿的疗效以及二者疗效比较.方法 对经间接检眼镜、荧光素眼底血管造影(FFA)以及光学相干断层扫描(OCT)检查确诊的RVO继发黄斑水肿患者91例91只眼,其中中央视网膜静脉阻塞(CR-VO)55只眼(缺血型13只眼,非缺血型42只眼),分支视网膜静脉阻塞(BRVO)36只眼(缺血型10只眼,非缺血26眼).糖尿病性黄斑水肿患者67例73只眼,非增殖性糖尿病视网膜病变(PPDR)17只眼,增殖性糖尿病视网膜病变(PDR)56只眼,行TA玻璃体腔注射,治疗后随访3月至1年,对比分析术前术后的视力、眼底、FFA表现,观察OCT显示黄斑水肿高度.结果 最终随访RVO组视力提高者48只眼(52.7%),视力不变者39只眼(42.9%),视力下降者4只眼(4.40%).OCT形态恢复正常者50只眼(54.9%),改善者27只眼(29.7%),无改善者14只眼(15.4%).DR组视力提高者25(34.2%)只眼,,视力不变者45只眼(61.6%),视力下降者3只眼(4.11%).OCT形态恢复正常者24只眼(32.9%),改善者22只眼(30.1%),无改善者27只眼(37.0%).两组有效率行统计学分析,有显著性差异.RVO组24只眼术后出现一过性眼压升高,一眼白内障,一眼眼内炎,8只眼2次注射.DR组14眼术后出现一过性眼压升高,2只眼白内障,9只眼2次注射.结论 玻璃体腔注射TA是一种安全有效的治疗视网膜静脉阻塞继发黄斑水肿和糖尿病性黄斑水肿的方法,治疗视网膜静脉阻塞继发黄斑水肿的疗效好于糖尿病性黄斑水肿.     

眶周注射曲安奈德治疗甲状腺相关眼病的临床研究

目的评价眶周注射曲安奈德治疗甲状腺相关眼病NOSPECSⅡ级患者的疗效。方法从169例甲状腺相关眼病连续病例中,随机选出NOSPECSⅡ级患者45例,其中38例为单眼发病,7例为双眼发病。第一组眶周注射曲安奈德,第二组予眶周注射曲安奈德同时口服强的松,第三组单纯口服强的松。每月记录CAS积分、睑裂大小、上睑迟落、角膜荧光素染色、泪膜破裂时间等,随访6月。结果三组治疗期间CAS积分、睑裂和上睑迟落均减小。第一组和第二组治疗后1~2月内CAS积分降至最小,而第三组于治疗后5月才降至最小,治疗后5月三组间CAS积分无明显差异。第一组和第二组于治疗后2月起睑裂开始缩小,第三组于治疗后3月起睑裂开始缩小,治疗后6月时第一组和第二组睑裂明显小于第三组。第一组和第二组于治疗后2月起上睑迟落开始减轻,第三组于治疗后3月起上睑迟落开始减轻,治疗后6月时第一组和第二组上睑迟落明显轻于第三组。三组治疗后角膜荧光素染色积分均减少,泪膜破裂时间改善,但三组间无明显差异。结论单纯上方眶周注射曲安奈德疗法与上方眶周注射曲安奈德联合口服强的松疗法较单纯口服强的松疗法能迅速、有效地改善甲状腺相关眼病NOSPECSⅡ级患者的症状和体征,第二种疗法与第一种疗法疗效相似,但存在全身副作用。     

曲安奈德对氪激光诱导的兔视网膜组织损伤的疗效观察

目的探讨曲安奈德(triamcinolone acetonide,TA)对氪激光诱导的青紫兰兔视网膜组织损伤的抑制作用,通过组织病理学检查,评价TA玻璃体腔内注射的安全性。方法选取成年、健康青紫兰兔12只,通过氪激光诱导建立激光损伤模型后,随机抽取6只兔右眼为A组,左眼为B组;另外6只兔右眼为C组,左眼为D组。每组玻璃体腔注射后14d和35d分别取3只兔处死,行组织病理学检查,每组各时间点随机选取光斑区30个CNV视野,选取连续切片的CNV最大中央厚度进行测量,用SPSS11．0软件进行统计分析。结果组织病理学检查发现, 光斑内CNV厚度和病变内细胞组成比例等方面表现不同,各时间点治疗组CNV中央厚度均较对照组显著减小,差异具有统计学意义(P<0．01);组织损伤修复的情况,A组较C组佳。结论 TA干预兔眼视网膜激光损伤的修复过程,早期进行药物干预,治疗效果佳。组织病理学检查,尚未发现TA的的毒副作用。     

玻璃体内注射曲安奈德治疗视网膜中央静脉 阻塞引起的黄斑囊样水肿

目的观察玻璃体内注射曲安奈德（TA）治疗视网膜中央静脉阻塞（CRVO）引起黄斑囊样水肿（CME）的疗效和安全性。方法14例CRVO所致CME患者14只眼玻璃体内注入40 mg/ml的TA0.1 ml。治疗前后均进行最佳矫正视力、眼压、裂隙灯显微镜、荧光素眼底血管造影（FFA）和光相干断层扫描（OCT）检查。随诊观察10.0～22.4个月，平均随诊观察时间为15.9个月。结果治疗前平均视力为0.1。治疗1、3个月时，100%的患眼视力提高，其中，视力≥0.2者分别为71.4%和63.6%，视力≥0.5者分别为42.9%和27.3%。此后，部分患者视力下降，最终随诊时视力≥0.2者占28.6%，≥0.5者占7.1%，与治疗前比较，71.4%的患眼视力有不同程度的提高，28.6%的患眼视力下降。治疗后1个月时，OCT检查显示黄斑水肿完全消退10只眼，占71.43%，水肿明显减轻4只眼，占28.57%。最终随诊时，OCT检查显示黄斑水肿完全消退4只眼，减轻9只眼，加重1只眼。7只眼在注射药物后1周～6个月期间先后出现不同程度的高眼压，眼压达到22.3～ 40.1 mm Hg（1 mm Hg = 0.133 kPa），在最终随诊时7只眼出现了晶状体后囊膜下混浊的并发性白内障。结论玻璃体内注射TA短期内能有效改善黄斑水肿和明显提高视力，部分治疗眼出现高眼压；远期观察黄斑水肿的复发率和晶状体后囊膜下混浊的发生率均较高。(中华眼底病杂志,2005,21:213-216)     

玻璃体注射曲安奈德联合视网膜光凝治疗黄斑水肿30眼

目的 观察玻璃体内注射曲安奈德联合多波长氪激光视网膜光凝治疗弥漫性黄斑水肿的疗效和安全性.方法 对符合入选条件的25例(30眼)弥漫性黄斑水肿患者行玻璃体腔内注射曲安奈德,水肿明显减轻或消失者行多波长氪激光视网膜光凝.结果 所有病例中有5眼视力稳定,2眼视力下降,23眼视力有不同程度提高.所有病例荧光素眼底血管造影均显示治疗后弥漫性黄斑水肿渗漏减轻或消失.5眼眼压大于21 mm Hg(1 mm Hg=0.133 kPa).结论玻璃体内注射曲安奈德联合多波长氪激光视网膜光凝治疗糖尿病性视网膜病变及视网膜静脉阻塞引起的弥漫性黄斑水肿不失为一种可取的方法 .     

Acute syphilitic posterior placoid chorioretinitis following intravitreal triamcinolone acetonide injection

Background  We describe the ophthalmic features and clinical course of two cases of acute syphilitic posterior placoid chorioretinitis (ASPPC) that developed after intravitreal triamcinolone acetonide (IVTA) injection. Methods  Case report. Results  Two patients with ocular inflammation of unknown origin developed severe chorioretinitis after IVTA injection. Multiple retinal infiltrates, placoid subretinal lesions, and ground-glass opacity of the retina with hyperemic optic discs were observed in both patients. The etiology of the chorioretinitis was confirmed by serology to be syphilis. Appropriate treatment for neurosyphilis was instituted. Both eyes became atrophied and had poor visual outcome: 10/200 in one patient and no light perception in the other at 6 months after IVTA injection. Conclusions  The fundus picture shown in these cases may be typical of ASPPC after IVTA injection. Clinical suspicion of ASPPC upon observation of these characteristic features is crucial for early diagnosis and treatment. The authors have no proprietary or financial interest in any of the products used in this study. The authors have full control of all primary data and agree to allow Graefe’s Archive for Clinical and Experimental Ophthalmology to review the data upon request.     

Natural history of sub-retinal triamcinolone acetonide deposition after triamcinolone-assisted vitrectomy

Purpose To describe the natural course of subretinal triamcinolone acetonide (TA) deposition after a TA-assisted vitrectomy for retinal detachment. Methods Observational case series. Results TA deposition was observed between the neurosensory retina and retinal pigment epithelium in the macular area at the conclusion of vitreoretinal surgery in three patients with retinal detachment. On follow up, TA granules gradually decreased over the next 2 weeks and resolved completely by 3 weeks. Two months after the operation, the retina was observed to be successfully attached and no ophthalmoscopic or functional damage was observed. Conclusion As no apparent clinically detectable adverse effect was found in the three cases that demonstrated subretinal deposition of TA we opine that active surgical maneuvers to remove the same are not warranted during surgery.     

地塞米松联合曲安奈德球后注射治疗视网膜静脉阻塞继发黄斑水肿的临床研究

目的 探讨早期球后注射地塞米松(DM)联合后期注射曲安奈德(TA)对视网膜静脉阻塞(RVO)继发黄斑水肿的治疗作用.方法 将我院眼科中心2年间83例(83只眼)确诊为视网膜静脉阻塞并继发黄斑水肿患者随机分为DM+TA组(41只眼)和TA组(42只眼).两组注药后,在指定的时间点(1、2周,1、2、3、4、5、6个月)分...